TRIAZOLONE COMPOUNDS AND USES THEREOF
The invention disclosed herein is directed to compounds of Formula (I) and pharmaceutically acceptable salts thereof, which are useful in the treatment of prostate, breast, colon, pancreatic, human chronic lymphocytic leukemia, melanoma and other cancers. The invention also comprises pharmaceutical...
Saved in:
Main Authors | , , , , , , , |
---|---|
Format | Patent |
Language | English French |
Published |
12.09.2013
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | The invention disclosed herein is directed to compounds of Formula (I) and pharmaceutically acceptable salts thereof, which are useful in the treatment of prostate, breast, colon, pancreatic, human chronic lymphocytic leukemia, melanoma and other cancers. The invention also comprises pharmaceutical compositions comprising a therapeutically effective amount of compound of Formula (I), or a pharmaceutically acceptable salt thereof. The invention disclosed herein is also directed to methods of treating prostate, breast, ovarian, liver, kidney, colon, pancreatic, human chronic lymphocytic leukemia, melanoma and other cancers. The invention disclosed herein is further directed to methods of treating prostate, breast, colon, pancreatic, chronic lymphocytic leukemia, melanoma and other cancers comprising administration of a of a therapeutically effective amount of a selective PPARalpha antagonist. The compounds and pharmaceutical compositions of the invention are also useful in the treatment of viral infections, such as HCV infections and HIV infections. The invention disclosed herein is also directed to a methods of preventing the onset of and/or recurrence of acute and chronic myeloid leukemia, as well as other cancers, comprising administration of a of a therapeutically effective amount of a selective PPARalpha antagonist.
La présente invention concerne des composés de formule (I) et des sels pharmaceutiquement acceptables de ceux-ci, qui sont utiles dans le traitement des cancers de la prostate, du sein, du côlon, du pancréas, de la leucémie lymphocytaire chronique humaine, du mélanome et d'autres cancers. L'invention concerne également des compositions pharmaceutiques comprenant une quantité thérapeutiquement efficace d'un composé de formule (I) ou d'un sel pharmaceutiquement acceptable de celui-ci. La présente invention concerne également des procédés de traitement des cancers de la prostate, du sein, de l'ovaire, du foie, du rein, du côlon, du pancréas, de la leucémie lymphocytaire chronique humaine, du mélanome et d'autres cancers. La présente invention concerne en outre des procédés de traitement de cancers de la prostate, du sein, du côlon, du pancréas, de la leucémie lymphocytaire chronique, du mélanome et d'autres cancers comprenant l'administration d'une quantité thérapeutiquement efficace d'un antagoniste sélectif de PPARalpha. Les composés et les compositions pharmaceutiques de l'invention sont également utiles dans le traitement d'infections virales, telles que les infections par le VHC et les infections par le VIH. La présente invention concerne également des procédés de prévention de l'apparition et/ou de la récidive de leucémie myéloïde aiguë et chronique, ainsi que d'autres cancers, comprenant l'administration d'une quantité thérapeutiquement efficace d'un antagoniste sélectif de PPARalpha. |
---|---|
AbstractList | The invention disclosed herein is directed to compounds of Formula (I) and pharmaceutically acceptable salts thereof, which are useful in the treatment of prostate, breast, colon, pancreatic, human chronic lymphocytic leukemia, melanoma and other cancers. The invention also comprises pharmaceutical compositions comprising a therapeutically effective amount of compound of Formula (I), or a pharmaceutically acceptable salt thereof. The invention disclosed herein is also directed to methods of treating prostate, breast, ovarian, liver, kidney, colon, pancreatic, human chronic lymphocytic leukemia, melanoma and other cancers. The invention disclosed herein is further directed to methods of treating prostate, breast, colon, pancreatic, chronic lymphocytic leukemia, melanoma and other cancers comprising administration of a of a therapeutically effective amount of a selective PPARalpha antagonist. The compounds and pharmaceutical compositions of the invention are also useful in the treatment of viral infections, such as HCV infections and HIV infections. The invention disclosed herein is also directed to a methods of preventing the onset of and/or recurrence of acute and chronic myeloid leukemia, as well as other cancers, comprising administration of a of a therapeutically effective amount of a selective PPARalpha antagonist.
La présente invention concerne des composés de formule (I) et des sels pharmaceutiquement acceptables de ceux-ci, qui sont utiles dans le traitement des cancers de la prostate, du sein, du côlon, du pancréas, de la leucémie lymphocytaire chronique humaine, du mélanome et d'autres cancers. L'invention concerne également des compositions pharmaceutiques comprenant une quantité thérapeutiquement efficace d'un composé de formule (I) ou d'un sel pharmaceutiquement acceptable de celui-ci. La présente invention concerne également des procédés de traitement des cancers de la prostate, du sein, de l'ovaire, du foie, du rein, du côlon, du pancréas, de la leucémie lymphocytaire chronique humaine, du mélanome et d'autres cancers. La présente invention concerne en outre des procédés de traitement de cancers de la prostate, du sein, du côlon, du pancréas, de la leucémie lymphocytaire chronique, du mélanome et d'autres cancers comprenant l'administration d'une quantité thérapeutiquement efficace d'un antagoniste sélectif de PPARalpha. Les composés et les compositions pharmaceutiques de l'invention sont également utiles dans le traitement d'infections virales, telles que les infections par le VHC et les infections par le VIH. La présente invention concerne également des procédés de prévention de l'apparition et/ou de la récidive de leucémie myéloïde aiguë et chronique, ainsi que d'autres cancers, comprenant l'administration d'une quantité thérapeutiquement efficace d'un antagoniste sélectif de PPARalpha. |
Author | BRAVO, YALDA, MOSTOFI STEARNS, BRIAN, ANDREW STOCK, NICHOLAS, SIMON JACINTHO, JASON, DUARTE SCOTT, JILL, MELISSA CHEN, AUSTIN, CHIH-YU TRUONG, YEN, PHAM CLARK, RYAN, CHRISTOPHER |
Author_xml | – fullname: STOCK, NICHOLAS, SIMON – fullname: CHEN, AUSTIN, CHIH-YU – fullname: BRAVO, YALDA, MOSTOFI – fullname: STEARNS, BRIAN, ANDREW – fullname: CLARK, RYAN, CHRISTOPHER – fullname: TRUONG, YEN, PHAM – fullname: SCOTT, JILL, MELISSA – fullname: JACINTHO, JASON, DUARTE |
BookMark | eNrjYmDJy89L5WRQDQnydIzy9_H3c1Vw9vcN8A_1cwlWcPRzUQgNdg1WCPFwDXL1d-NhYE1LzClO5YXS3AzKbq4hzh66qQX58anFBYnJqXmpJfHh_kYGhsaGxiamZkaOhsbEqQIAK54mDw |
ContentType | Patent |
DBID | EVB |
DatabaseName | esp@cenet |
DatabaseTitleList | |
Database_xml | – sequence: 1 dbid: EVB name: esp@cenet url: http://worldwide.espacenet.com/singleLineSearch?locale=en_EP sourceTypes: Open Access Repository |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine Chemistry Sciences |
DocumentTitleAlternate | COMPOSÉS DE TRIAZOLONE ET LEURS UTILISATIONS |
ExternalDocumentID | WO2013134562A1 |
GroupedDBID | EVB |
ID | FETCH-epo_espacenet_WO2013134562A13 |
IEDL.DBID | EVB |
IngestDate | Fri Jul 19 16:00:11 EDT 2024 |
IsOpenAccess | true |
IsPeerReviewed | false |
IsScholarly | false |
Language | English French |
LinkModel | DirectLink |
MergedId | FETCHMERGED-epo_espacenet_WO2013134562A13 |
Notes | Application Number: WO2013US29713 |
OpenAccessLink | https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20130912&DB=EPODOC&CC=WO&NR=2013134562A1 |
ParticipantIDs | epo_espacenet_WO2013134562A1 |
PublicationCentury | 2000 |
PublicationDate | 20130912 |
PublicationDateYYYYMMDD | 2013-09-12 |
PublicationDate_xml | – month: 09 year: 2013 text: 20130912 day: 12 |
PublicationDecade | 2010 |
PublicationYear | 2013 |
RelatedCompanies | INCEPTION 2, INC |
RelatedCompanies_xml | – name: INCEPTION 2, INC |
Score | 2.8964527 |
Snippet | The invention disclosed herein is directed to compounds of Formula (I) and pharmaceutically acceptable salts thereof, which are useful in the treatment of... |
SourceID | epo |
SourceType | Open Access Repository |
SubjectTerms | CHEMISTRY HETEROCYCLIC COMPOUNDS HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS |
Title | TRIAZOLONE COMPOUNDS AND USES THEREOF |
URI | https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20130912&DB=EPODOC&locale=&CC=WO&NR=2013134562A1 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1bS8MwFD6MKeqbTsXLlILat-J6NXsY0vVCFduU2urwZTRdCoLM4Sr-fU9Cp3vaW0jg5ALn8iX5zgG4LtEpYdzNtJlDmGbpVa0RVnKNEEG8rh1eMUFwjhMnKqzHiT3pwMeKCyPzhP7I5IioURXqeyPt9eL_EsuXfyuXt-wduz7vw3zkqy06RoM81A3VH4-ClPrUUz0PcZuaZHJMN0W47yJW2hKBtMi0H7yMBS9lse5Uwn3YTlHevDmADp_3YNdb1V7rwU7cPnljs9W-5SHc5NmD-0afaBIoHo1TWiT-s-ImvlKgVVTyKMgCGh7BVRjkXqThfNO_7U1f6frizGPoIvDnJ6Dow9omFdHvSruyOEEsaTtkYNq8JjWzB8Yp9DdJOts8fA57hiztIMoh9KHbfH3zC3SwDbuU5_ILphh53g |
link.rule.ids | 230,309,786,891,25594,76906 |
linkProvider | European Patent Office |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1bS8MwFD6MKc43nYqXqQW1b8W1a7vsYUjXC52uzaidjr2MpqYgyByu4t_3JHS6p72FBE4ucC5fku8cgNsMnRLG3Ux7swnTTD0vNMIyrhEiiNeFzXMmCM5RbIcT83FqTWvwsebCyDyhPzI5ImpUjvpeSnu9_L_E8uTfytU9e8euz4cg7XtqhY7RIPd0Q_UGfX9MPeqqrou4TY0TOaZ3RLjvIFba6Yr8vCJ4ehkIXspy06kEB7A7RnmL8hBqfNGEhruuvdaEvah68sZmpX2rI7hLk6EzoyMa-4pLozGdxN6z4sSeMkGrqKShn_g0OIabwE_dUMP55n_bm7_SzcV1TqCOwJ-fgqL3CovkRO9mVm5ygljSskm7Y_GCFMxqG2fQ2ibpfPvwNTTCNBrNR8P46QL2DVnmQZRGaEG9_Prml-hsS3Ylz-gXgR98yw |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Apatent&rft.title=TRIAZOLONE+COMPOUNDS+AND+USES+THEREOF&rft.inventor=STOCK%2C+NICHOLAS%2C+SIMON&rft.inventor=CHEN%2C+AUSTIN%2C+CHIH-YU&rft.inventor=BRAVO%2C+YALDA%2C+MOSTOFI&rft.inventor=STEARNS%2C+BRIAN%2C+ANDREW&rft.inventor=CLARK%2C+RYAN%2C+CHRISTOPHER&rft.inventor=TRUONG%2C+YEN%2C+PHAM&rft.inventor=SCOTT%2C+JILL%2C+MELISSA&rft.inventor=JACINTHO%2C+JASON%2C+DUARTE&rft.date=2013-09-12&rft.externalDBID=A1&rft.externalDocID=WO2013134562A1 |